The number that landed Thursday morning deserves a moment: China-based biotech companies’ deals to license the commercialisation of their drugs in overseas markets reached $139.4 billion for the year to October 8, 2026, according to data provider PharmCube, as Reuters reported Friday. Last year, the total value, including milestone payments, reached $138.8 billion. This year’s figure surpassed that with almost three months still to run.
The pace alone is striking. But the more consequential change is structural. This is no longer a story about cheap Chinese molecules filling gaps in Western pipelines. It is about who ends up owning the economics of medicine for the next ten years.
Big Pharma’s R&D Department Has Moved East
Chinese sources accounted for roughly 5% of large pharma licensing activity just four years ago. By 2025 that figure had climbed to 38%, and by early 2026 it had crossed the majority threshold, Reuters reported. The three deals that defined this year’s surge tell the story plainly. CSPC Pharmaceutical Group partnered with AstraZeneca for up to $18.5 billion, Hengrui Medicine partnered with Bristol Myers Squibb for up to $15.2 billion, and Innovent Biologics partnered with Pfizer for up to $10.5 billion.
Pfizer, AstraZeneca, and BMS are not speculating. They are replacing internal R&D capacity they can no longer build fast enough or cheaply enough on their own. Deal structure is shifting from individual products to licensing platforms and bundled early-stage assets, with AI-driven drug discovery emerging as a disruptive new force.
Hengrui: The Compounder Inside the Wave
Among Chinese biotechs, Hengrui Pharma stands apart as the most instructive case for long-term investors. Hengrui has announced international licensing and collaboration deals since 2023 with an aggregate potential total value of about $42 billion. The range of therapeutic areas covered is no longer narrow. On September 29, 2026, Hengrui entered a deal with Novo Nordisk for HRS-1596, a once-weekly oral GLP-1 and GIP receptor dual agonist. The agreement carries a potential total value of up to $2.6 billion, including $300 million upfront, and includes potential applications in obesity, type 2 diabetes, and other metabolic diseases. That puts Hengrui inside the incretin boom, the single most valuable therapeutic category in global pharma today.
Critically, the terms are changing in Hengrui’s favor. In 2025, upfront payments from Chinese companies’ outbound licensing deals reached $7.0 billion, according to PharmCube data cited in a Hong Kong Stock Exchange filing. And Hengrui is not simply selling molecules. Its May agreement with BMS covers 13 early-stage programs. Under that set of agreements, BMS can license up to four Hengrui programs for development and commercialization outside of Greater China, while Hengrui can license up to two BMS programs for development and commercialization in mainland China, Hong Kong, and Macau. That is an asset exchange between equals, not a supplier handing goods to a customer.
The Economics Question That Matters Most
Here is where disciplined investors need to think carefully. For Chinese biotechs, the cheap era is ending on favorable terms. Hengrui raised about $1.26 billion in its Hong Kong listing in May 2025. Companies that had no leverage during the 2022 funding drought now face a genuine choice: license out for near-term cash, or hold an asset and develop it alone.
Firms with real late-stage execution will increasingly choose to hold, which raises an uncomfortable possibility for buyers. The deals being signed today may be the last generation at current valuations. Western pharma is already competing against each other for access to the same Chinese labs.
For investors in XBI or in the major Western licensees, the calculation is not symmetrical. AstraZeneca, Merck, and Pfizer are paying for pipeline survival. Hengrui, at roughly a mid-$40 billion market capitalization in early October 2026, is compounding its own royalty streams, its own balance sheet, and now its own in-licensed assets from the West. The drug discovery center of gravity has moved. The question is whether the ownership of the resulting profits has followed it there yet.
